162 related articles for article (PubMed ID: 35724920)
1. Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment.
Hagan CT; Bloomquist C; Kim I; Knape NM; Byrne JD; Tu L; Wagner K; Mecham S; DeSimone J; Wang AZ
Acta Biomater; 2022 Aug; 148():163-170. PubMed ID: 35724920
[TBL] [Abstract][Full Text] [Related]
2. 3D printed drug-loaded implantable devices for intraoperative treatment of cancer.
Hagan CT; Bloomquist C; Warner S; Knape NM; Kim I; Foley H; Wagner KT; Mecham S; DeSimone J; Wang AZ
J Control Release; 2022 Apr; 344():147-156. PubMed ID: 35217100
[TBL] [Abstract][Full Text] [Related]
3. Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins.
Bloomquist CJ; Mecham MB; Paradzinsky MD; Janusziewicz R; Warner SB; Luft JC; Mecham SJ; Wang AZ; DeSimone JM
J Control Release; 2018 May; 278():9-23. PubMed ID: 29596874
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy.
Kumar R; Belz J; Markovic S; Jadhav T; Fowle W; Niedre M; Cormack R; Makrigiorgos MG; Sridhar S
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):393-400. PubMed ID: 25636762
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
6. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices.
Cormack RA; Sridhar S; Suh WW; D'Amico AV; Makrigiorgos GM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):615-23. PubMed ID: 19879699
[TBL] [Abstract][Full Text] [Related]
7. Low-cost 3D print-based phantom fabrication to facilitate interstitial prostate brachytherapy training program.
Chiu T; Xiong Z; Parsons D; Folkert MR; Medin PM; Hrycushko B
Brachytherapy; 2020; 19(6):800-811. PubMed ID: 32690386
[TBL] [Abstract][Full Text] [Related]
8. Optical fibre based real-time measurements during an LDR prostate brachytherapy implant simulation: using a 3D printed anthropomorphic phantom.
Woulfe P; Sullivan FJ; Byrne L; Doyle AJ; Kam W; Martyn M; O'Keeffe S
Sci Rep; 2021 May; 11(1):11160. PubMed ID: 34045648
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
12. 3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results.
Martin T; Hey-Koch S; Strassmann G; Kolotas C; Baltas D; Rogge B; Röddiger S; Vogt HG; Heyd R; Dannenberg T; Kurek R; Tunn U; Zamboglou N
Strahlenther Onkol; 2000 Aug; 176(8):361-7. PubMed ID: 10987019
[TBL] [Abstract][Full Text] [Related]
13. High dose rate brachytherapy in the treatment of prostate cancer.
Vicini F; Vargas C; Gustafson G; Edmundson G; Martinez A
World J Urol; 2003 Sep; 21(4):220-8. PubMed ID: 12905008
[TBL] [Abstract][Full Text] [Related]
14. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
15. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method.
Kang SK; Chou RH; Dodge RK; Clough RW; Kang HL; Bowen MG; Steffey BA; Das SK; Zhou SM; Whitehurst AW; Buckley NJ; Kim JH; Joyner RE; Sarmina I; Montana GS; Ingram SS; Anscher MS
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):937-45. PubMed ID: 11429221
[TBL] [Abstract][Full Text] [Related]
16. Does brachytherapy have a role in the treatment of prostate cancer?
Grimm PD; Blasko JC; Ragde H; Sylvester J; Clarke D
Hematol Oncol Clin North Am; 1996 Jun; 10(3):653-73. PubMed ID: 8773503
[TBL] [Abstract][Full Text] [Related]
17. Localization of linked 125I seeds in postimplant TRUS images for prostate brachytherapy dosimetry.
Xue J; Waterman F; Handler J; Gressen E
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):912-9. PubMed ID: 15936577
[TBL] [Abstract][Full Text] [Related]
18. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
19. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.
Zelefsky MJ; Yamada Y; Marion C; Sim S; Cohen G; Ben-Porat L; Silvern D; Zaider M
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):956-63. PubMed ID: 12605973
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes.
Yang G; Strom TJ; Wilder RB; Shrinath K; Mellon EA; Fernandez DC; Biagioli MC
Int Braz J Urol; 2015; 41(3):435-41. PubMed ID: 26200536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
